Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Pazdur says the time has come for an Oncologic Drugs Advisory Committee meeting devoted to issues surrounding use of progression-free survival endpoints - including clinical relevance.

You may also be interested in...



FDA Oncology Panel To Weigh Independent Review Of PFS Event Subset

The Oncologic Drugs Advisory Committee’s July 24 meeting to discuss the merits of independent radiological review of progression assessments in a pre-specified subgroup of patients, instead of 100% of all assessments, comes three years after the agency signaled it was open to considering such an approach.

AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications

An updated analysis showing no overall survival advantage for vandetanib, plus feedback from both FDA and EMEA that progression-free survival was not enough, caused AstraZeneca to withdraw the filings.

AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications

An updated analysis showing no overall survival advantage for vandetanib, plus feedback from both FDA and EMEA that progression-free survival was not enough, caused AstraZeneca to withdraw the filings.

Related Content

Topics

UsernamePublicRestriction

Register

PS069980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel